Barclays Keeps Their Hold Rating on IQVIA Holdings (IQV)

In a report released today, Luke Sergott from Barclays maintained a Hold rating on IQVIA Holdings, with a price target of $210.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Sergott covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, Mettler-Toledo, and Twist Bioscience. According to TipRanks, Sergott has an average return of -0.2% and a 45.58% success rate on recommended stocks.

In addition to Barclays, IQVIA Holdings also received a Hold from TipRanks – Google’s Google Medical – Diagnostics and Research in a report issued on February 4. However, yesterday, William Blair reiterated a Buy rating on IQVIA Holdings (NYSE: IQV).

Based on IQVIA Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $4.1 billion and a net profit of $331 million. In comparison, last year the company earned a revenue of $3.9 billion and had a net profit of $285 million

Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IQV in relation to earlier this year. Most recently, in December 2025, Ari Bousbib, the Chairman, CEO & President of IQV sold 36,564.00 shares for a total of $8,132,930.52.